# Becton Dickinson and Company (BDX) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Health Care Equipment & Supplies. Price $184.74, market value $50.3 billion.

## Valuation
- **P/E (trailing): 32.0×** (5-yr avg 29.6×, 3-yr avg 31.6×). Becton Dickinson and Company trades at 32.0× trailing earnings, close to its own five-year average of 29.6×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 13.9×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 2.3×**. Each dollar of revenue is priced at 2.3×.
- **Price / book: 2.1×**. The shares trade at 2.1× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 15.3×**. Enterprise value is 15.3× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 5.4%** (5-yr avg 5.2%). Free cash flow equals 5.4% of the market value, in line with its five-year average of 5.2%. Above 5% is generally attractive.
- **Earnings yield: 3.1%**. The inverse of the P/E: 3.1% of the price is earned each year.

## Profitability
- **Operating margin: 10.0%**. 10.0% of revenue is left after running the business.
- **Net margin: 7.7%**. 7.7% of each dollar of sales reaches the bottom line.
- **Return on equity: 6.6%**. 6.6% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 3.9%**. Return on all capital, debt included, is 3.9%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.7%**. Each dollar of assets produces 1.7% of profit.

## Growth
- **Revenue growth (1 yr): 8.2%** (3-yr 5.0%/yr, 5-yr 6.3%/yr). Revenue grew 8.2% over the last year, against 6.3% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): -0.7%** (3-yr -0.3%/yr, 5-yr 16.5%/yr). Earnings per share fell 0.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): 21.2%/yr**. Free cash flow has compounded at 21.2% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.76**. Debt is 0.76 times equity, moderate leverage.
- **Net debt / EBITDA: 4.1×**. It would take 4.1 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 2.27%** ($4.19 per share, trailing). Becton Dickinson and Company yields 2.27%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 71%** (43% of free cash flow). 71% of earnings goes out as dividends, leaving a thin cushion.
- **Consecutive years of increases: 26**. 26 straight years of increases (the data covers 26 years, so this may be longer): a record very few companies hold.
- **Dividend growth (5 yr): 6.0%/yr** (1-yr 7.2%). The dividend has grown 6.0% a year over five years.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover Becton Dickinson and Company; the consensus is buy, with an average price target of $194.42 (+5% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 25.9%** (YTD 22.7%, 3-mo 23.1%). The shares are up 25.9% over twelve months including dividends.
- **From 52-week high: -4.3%** (44.8% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 58**. An RSI of 58 is neutral.
- **Beta (1 yr): 0.37** (volatility 26%). Beta of 0.37 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BDX · Page: https://foliofundamentals.com/stocks/bdx

Not investment advice.